Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B

  • Technology appraisal guidance
  • TA96
  • Published: 
Download guidance (PDF)

Appendix B. Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by Southampton Health Technology Assessment Centre ( SHTAC), University of Southampton:

  • Shepherd J, Jones J, Takeda A, et al. 'Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B – a systematic review and economic evaluation', May 2005.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, the Assessment Report and the Appraisal Consultation Document. Consultee organisations are provided with the opportunity to appeal against the Final Appraisal Determination:

I) Manufacturers/sponsors:

  • Gilead Sciences

  • Roche Products.

II) Professional/specialist and patient/carer groups:

  • African Caribbean Medical Society

  • British Association for Sexual Health and HIV

  • British Association for the Study of the Liver

  • British Liver Trust

  • British Society of Gastroenterology

  • Chinese National Healthy Living Centre

  • Health Protection Agency

  • Hepatitis Nurse Specialist Forum

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • UK Clinical Virology Network

  • Welsh Assembly Government.

III) Commentator organisations (without the right of appeal):

  • British National Formulary

  • NHS Quality Improvement Scotland

  • GlaxoSmithKline

  • Foundation for Liver Research (formerly the Liver Research Trust)

  • MRC Clinical Trials Unit

  • Southampton Health Technology Assessment Centre (SHTAC).

C. The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on adefovir dipivoxil and peginterferon alfa-2a by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the Appraisal Consultation Document:

  • Professor Geoffrey Dusheiko, Professor of Medicine, Royal Free University College School of Medicine – nominated by the Royal College of Physicians

  • Professor Howard Thomas, Professor of Medicine, Imperial College London – nominated by the British Association for the Study of the Liver.